139 related articles for article (PubMed ID: 26124938)
1. Preparation and characterization of different liposomal formulations containing P5 HER2/neu-derived peptide and evaluation of their immunological responses and antitumor effects.
Shariat S; Badiee A; Amir Jalali S; Mansourian M; Alireza Mortazavi S; Reza Jaafari M
Iran J Basic Med Sci; 2015 May; 18(5):506-13. PubMed ID: 26124938
[TBL] [Abstract][Full Text] [Related]
2. P5 HER2/neu-derived peptide conjugated to liposomes containing MPL adjuvant as an effective prophylactic vaccine formulation for breast cancer.
Shariat S; Badiee A; Jalali SA; Mansourian M; Yazdani M; Mortazavi SA; Jaafari MR
Cancer Lett; 2014 Dec; 355(1):54-60. PubMed ID: 25224570
[TBL] [Abstract][Full Text] [Related]
3. MPL nano-liposomal vaccine containing P5 HER2/neu-derived peptide pulsed PADRE as an effective vaccine in a mice TUBO model of breast cancer.
Zamani P; Navashenaq JG; Nikpoor AR; Hatamipour M; Oskuee RK; Badiee A; Jaafari MR
J Control Release; 2019 Jun; 303():223-236. PubMed ID: 30999007
[TBL] [Abstract][Full Text] [Related]
4. Preparation of nanoliposomes linked to HER2/neu-derived (P5) peptide containing MPL adjuvant as vaccine against breast cancer.
Rastakhiz S; Yazdani M; Shariat S; Arab A; Momtazi-Borojeni AA; Barati N; Mansourian M; Amin M; Abbasi A; Saberi Z; Jalali SA; Badiee A; Jaafari MR
J Cell Biochem; 2019 Feb; 120(2):1294-1303. PubMed ID: 30378147
[TBL] [Abstract][Full Text] [Related]
5. Conjugated nanoliposome with the HER2/neu-derived peptide GP2 as an effective vaccine against breast cancer in mice xenograft model.
Razazan A; Behravan J; Arab A; Barati N; Arabi L; Gholizadeh Z; Hatamipour M; Reza Nikpoor A; Momtazi-Borojeni AA; Mosaffa F; Ghahremani MH; Jaafari MR
PLoS One; 2017; 12(10):e0185099. PubMed ID: 29045460
[TBL] [Abstract][Full Text] [Related]
6. Effective induction of anti-tumor immunity using p5 HER-2/neu derived peptide encapsulated in fusogenic DOTAP cationic liposomes co-administrated with CpG-ODN.
Mansourian M; Badiee A; Jalali SA; Shariat S; Yazdani M; Amin M; Jaafari MR
Immunol Lett; 2014 Nov; 162(1 Pt A):87-93. PubMed ID: 25086399
[TBL] [Abstract][Full Text] [Related]
7. Poly (I:C)-DOTAP cationic nanoliposome containing multi-epitope HER2-derived peptide promotes vaccine-elicited anti-tumor immunity in a murine model.
Alipour Talesh G; Ebrahimi Z; Badiee A; Mansourian M; Attar H; Arabi L; Jalali SA; Jaafari MR
Immunol Lett; 2016 Aug; 176():57-64. PubMed ID: 27260485
[TBL] [Abstract][Full Text] [Related]
8. Preparation of nanoliposomes containing HER2/neu (P5+435) peptide and evaluation of their immune responses and anti-tumoral effects as a prophylactic vaccine against breast cancer.
Naghibi L; Yazdani M; Momtazi-Borojeni AA; Razazan A; Shariat S; Mansourian M; Arab A; Barati N; Arabsalmani M; Abbasi A; Saberi Z; Badiee A; Jalali SA; Jaafari MR
PLoS One; 2020; 15(12):e0243550. PubMed ID: 33301467
[TBL] [Abstract][Full Text] [Related]
9. Stimulation of Tumor-Specific Immunity by p5 HER-2/neu Generated Peptide Encapsulated in Nano-liposomes with High Phase Transition Temperature Phospholipids.
Yazdani M; Jalali SA; Badiee A; Shariat S; Mansourian M; Arabi L; Abbasi A; Saberi Z; Jaafari MR
Curr Drug Deliv; 2017; 14(4):492-502. PubMed ID: 27411392
[TBL] [Abstract][Full Text] [Related]
10. A nano-liposome vaccine carrying E75, a HER-2/neu-derived peptide, exhibits significant antitumour activity in mice.
Arab A; Behravan J; Razazan A; Gholizadeh Z; Nikpoor AR; Barati N; Mosaffa F; Badiee A; Jaafari MR
J Drug Target; 2018 Apr; 26(4):365-372. PubMed ID: 28972792
[TBL] [Abstract][Full Text] [Related]
11. P435 HER2/neu-derived peptide conjugated to liposomes containing DOPE as an effective prophylactic vaccine formulation for breast cancer.
Farzad N; Barati N; Momtazi-Borojeni AA; Yazdani M; Arab A; Razazan A; Shariat S; Mansourian M; Abbasi A; Saberi Z; Badiee A; Jalali SA; Jaafari MR
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):665-673. PubMed ID: 30829072
[TBL] [Abstract][Full Text] [Related]
12. Enhanced immune response induced by P5 HER2/neu-derived peptide-pulsed dendritic cells as a preventive cancer vaccine.
Gholizadeh Z; Tavakkol-Afshari J; Nikpoor AR; Jalali SA; Jaafari MR
J Cell Mol Med; 2018 Jan; 22(1):558-567. PubMed ID: 28944998
[TBL] [Abstract][Full Text] [Related]
13. Improved Immunogenicity Against a Her2/neu-Derived Peptide by Employment of a Pan HLA DR-Binding Epitope and CpG in a BALB/c Mice Model.
Tahaghoghi-Hajghorbani S; Tavakkol-Afshari J; Jaafari MR; Ghaffari-Nazari H; Masoumi E; Jalali SA
Anticancer Agents Med Chem; 2017; 17(6):851-858. PubMed ID: 27924731
[TBL] [Abstract][Full Text] [Related]
14. Optimization of a Method to Prepare Liposomes Containing HER2/Neu- Derived Peptide as a Vaccine Delivery System for Breast Cancer.
Shariat S; Badiee A; Jaafari MR; Mortazavi SA
Iran J Pharm Res; 2014; 13(Suppl):15-25. PubMed ID: 24711825
[TBL] [Abstract][Full Text] [Related]
15. Effective induction of CD8+ T-cell response using CpG oligodeoxynucleotides and HER-2/neu-derived peptide co-encapsulated in liposomes.
Li WM; Dragowska WH; Bally MB; Schutze-Redelmeier MP
Vaccine; 2003 Jul; 21(23):3319-29. PubMed ID: 12804863
[TBL] [Abstract][Full Text] [Related]
16. Nanoliposomes carrying HER2/neu-derived peptide AE36 with CpG-ODN exhibit therapeutic and prophylactic activities in a mice TUBO model of breast cancer.
Barati N; Nikpoor AR; Razazan A; Mosaffa F; Badiee A; Arab A; Gholizadeh Z; Behravan J; Jaafari MR
Immunol Lett; 2017 Oct; 190():108-117. PubMed ID: 28736158
[TBL] [Abstract][Full Text] [Related]
17. Potent CD4+ T-cell epitope P30 enhances HER2/neu-engineered dendritic cell-induced immunity against Tg1-1 breast cancer in transgenic FVBneuN mice by enhanced CD4+ T-cell-stimulated CTL responses.
Xie Y; Chen Y; Ahmed KA; Li W; Ahmed S; Sami A; Chibbar R; Tang X; Tao M; Xu J; Xiang J
Cancer Gene Ther; 2013 Oct; 20(10):590-8. PubMed ID: 24052129
[TBL] [Abstract][Full Text] [Related]
18. Induction of tumor-specific immunity by multi-epitope rat HER2/neu-derived peptides encapsulated in LPD Nanoparticles.
Jalali SA; Sankian M; Tavakkol-Afshari J; Jaafari MR
Nanomedicine; 2012 Jul; 8(5):692-701. PubMed ID: 22024191
[TBL] [Abstract][Full Text] [Related]
19. Immunoliposomes bearing lymphocyte activation gene 3 fusion protein and P5 peptide: A novel vaccine for breast cancer.
Mohammadian Haftcheshmeh S; Zamani P; Mashreghi M; Nikpoor AR; Tavakkol-Afshari J; Jaafari MR
Biotechnol Prog; 2021 Mar; 37(2):e3095. PubMed ID: 33118322
[TBL] [Abstract][Full Text] [Related]
20. Comparison of two different PEGylation strategies for the liposomal adjuvant CAF09: Towards induction of CTL responses upon subcutaneous vaccine administration.
Schmidt ST; Olsen CL; Franzyk H; Wørzner K; Korsholm KS; Rades T; Andersen P; Foged C; Christensen D
Eur J Pharm Biopharm; 2019 Jul; 140():29-39. PubMed ID: 31055066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
